CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.406
EU - Europa 10.026
AS - Asia 8.247
SA - Sud America 1.054
Continente sconosciuto - Info sul continente non disponibili 258
AF - Africa 177
OC - Oceania 14
Totale 31.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.203
RU - Federazione Russa 3.701
SG - Singapore 3.183
CN - Cina 2.770
GB - Regno Unito 2.143
IT - Italia 930
BR - Brasile 801
VN - Vietnam 671
HK - Hong Kong 650
DE - Germania 624
FR - Francia 608
FI - Finlandia 540
IE - Irlanda 497
SE - Svezia 490
KR - Corea 269
BD - Bangladesh 141
IN - India 140
NL - Olanda 115
UA - Ucraina 104
CA - Canada 89
AR - Argentina 88
JP - Giappone 64
ID - Indonesia 57
TR - Turchia 53
MX - Messico 49
PL - Polonia 49
EC - Ecuador 48
ZA - Sudafrica 48
IQ - Iraq 45
ES - Italia 42
BE - Belgio 33
CH - Svizzera 28
CO - Colombia 27
AT - Austria 25
CL - Cile 25
PK - Pakistan 25
MA - Marocco 24
VE - Venezuela 23
NG - Nigeria 22
SA - Arabia Saudita 18
PY - Paraguay 17
PH - Filippine 16
UZ - Uzbekistan 16
CR - Costa Rica 15
IR - Iran 15
EU - Europa 14
MY - Malesia 14
NP - Nepal 14
CZ - Repubblica Ceca 13
LT - Lituania 13
PE - Perù 13
TN - Tunisia 13
EG - Egitto 12
KE - Kenya 12
AZ - Azerbaigian 11
JM - Giamaica 11
TG - Togo 11
AU - Australia 10
AE - Emirati Arabi Uniti 9
HN - Honduras 9
TH - Thailandia 9
AL - Albania 8
BJ - Benin 8
LV - Lettonia 8
DZ - Algeria 7
OM - Oman 7
PT - Portogallo 7
RS - Serbia 7
BO - Bolivia 6
GR - Grecia 6
NI - Nicaragua 6
AM - Armenia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
IL - Israele 5
JO - Giordania 5
KZ - Kazakistan 4
MK - Macedonia 4
NO - Norvegia 4
SV - El Salvador 4
UY - Uruguay 4
BG - Bulgaria 3
CI - Costa d'Avorio 3
CM - Camerun 3
CY - Cipro 3
GA - Gabon 3
GE - Georgia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
RO - Romania 3
SI - Slovenia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
BS - Bahamas 2
EE - Estonia 2
Totale 30.896
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Singapore 1.592
San Jose 1.188
Moscow 1.145
Chandler 1.084
Ashburn 998
Woodbridge 955
Dallas 848
Hong Kong 642
Ann Arbor 620
Dublin 492
Beijing 486
Council Bluffs 456
Jacksonville 445
The Dalles 445
Houston 413
Verona 364
Jinan 247
Ho Chi Minh City 241
Lawrence 237
Princeton 236
New York 213
Wilmington 192
Los Angeles 188
Nanjing 187
Munich 186
Shenyang 157
Hanoi 155
Helsinki 131
Hebei 118
Buffalo 106
Redondo Beach 106
Tianjin 106
Santa Clara 101
Changsha 80
Ningbo 77
São Paulo 74
Milan 72
Haikou 70
Guangzhou 62
Zhengzhou 60
Nanchang 59
Hangzhou 57
Sindelfingen 54
Tokyo 54
Columbus 53
Jiaxing 49
London 49
Frankfurt am Main 47
Taizhou 47
Seoul 45
Orem 40
Turku 39
Taiyuan 38
Seattle 37
Chennai 36
Chicago 36
Brussels 33
Fuzhou 30
Montreal 30
Warsaw 30
Rio de Janeiro 29
Rome 29
Brooklyn 28
San Francisco 28
Amsterdam 27
Boardman 26
Denver 26
Johannesburg 26
Lanzhou 26
Norwalk 26
Falls Church 24
Lancaster 24
Redwood City 24
Dearborn 23
Mexico City 22
Abuja 21
Mumbai 21
Phoenix 21
Stockholm 21
Da Nang 20
Haiphong 20
Quito 20
Atlanta 19
Baghdad 19
Boston 18
Jakarta 18
Zurich 18
Hải Dương 17
Nuremberg 17
Belo Horizonte 16
Bologna 16
Porto Alegre 16
Shanghai 16
Charlotte 15
Madrid 15
Meda 15
Biên Hòa 14
Curitiba 14
Poplar 14
Totale 19.133
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 314
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 289
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 251
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 248
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 244
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 237
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 229
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 225
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 215
Adenocarcinoma of the paraurethral glands: a case report 214
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 214
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 213
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 209
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 204
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 203
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 202
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 202
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 201
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 201
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 200
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 198
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 195
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 195
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 194
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 193
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 192
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 192
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 190
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 189
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 188
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 184
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 184
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 182
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 181
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 180
The development of PARP as a successful target for cancer therapy 180
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 180
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 179
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 178
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 178
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 178
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 177
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 172
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 172
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 172
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 172
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 168
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 168
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 168
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 166
Do immune checkpoint inhibitors need new studies methodology? 165
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies 165
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 164
2-weekly docetaxel: issues for clinical practice. 162
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 162
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 162
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 161
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 160
Clinical meta-analyses of targeted therapies in adenocarcinoma. 160
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 156
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 155
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 154
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 153
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 150
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 149
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 147
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 146
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 146
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 146
Acute emesis: Moderately emetogenic chemotherapy. 145
Clinical meta-analyses of targeted therapies in adenocarcinoma. 143
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 143
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 143
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 141
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 139
Physical activity and exercise in lung cancer care: will promises be fulfilled? 137
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 137
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 137
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 137
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 135
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 135
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 135
Adjuvant chemotherapy for bladder cancer: the chance for meta-aalyses comparison 133
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 133
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 132
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 131
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 131
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 131
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 130
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 129
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 129
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 129
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 128
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 127
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 125
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 125
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 125
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 124
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 123
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 122
Totale 17.037
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.706
article - articoli 107.292
book - libri 536
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.878
Totale 227.412
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.556 0 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/20254.445 234 266 173 799 134 157 160 215 751 326 329 901
2025/202612.795 961 701 925 1.991 3.120 766 1.218 676 1.045 724 283 385
2026/2027518 147 371 0 0 0 0 0 0 0 0 0 0
Totale 31.182